Background and Definitions

Definitions
In the most recent version of the Chapel Hill nomenclature of vasculitis the disease entity "Anti-glomerular basement membrane disease" (anti-GBM-disease) is included among immune complex small vessel vasculitides [1] . The definition anti-GBM disease according this document is a vasculitis affecting glomerular capillaries, pulmonary capillaries, or both, with GBM deposition of anti-GBM autoantibodies. Lung involvement causes pulmonary haemorrhage, and renal involvement causes glomerulonephritis with necrosis and crescents. It is noted in the document that the terms anti-GBM disease and anti-GBM-antibodies is somewhat confusing as the antibodies react also with the alveolar basement membrane.
History
The history of what we today call anti-GBM disease dates back to 1958 when Stanton et al reported as series of patients with the combination of glomerulonephritis and lung haemorrhage and introduced the term Goodpasture's syndrome in recognition of a case report from 1919 by E.W. Goodpasture [2, 3] . When the technique for direct immunofluorescence (IF) was introduced in renal medicine it was shown that such patients often had a continuous linear deposition of immunoglobulin G along their glomerular basement membrane (figure 1). A pathogenic role of these antibodies was demonstrated by elution of autoantibodies from human kidneys and transfer to primates [4] . This led to a tendency to narrow the use of the term Goodpasture's syndrome to include only cases with the triad of lung haemorrhage, renal failure and anti-GBM antibodies. Later when it was shown that many patients with anti-GBM do not have lung haemorrhage and most patients with lung haemorrhage and glomerulonephritis do not have anti-GBM, the term Goodpasture's disease was preferred for anti-GBM in conjunction with glomerulonephritis and/or alveolar bleeding.
Pathogenesis
Anti-GBM disease is a prototype of autoimmune disease, where B-and T-cell mediated responses constitute the basis of the pathogenic process. The patients develop autoantibodies against the non-collagenous domain 1 of the 3-chain of type IV collagen (3(IV)NC1) [5] . The 3(IV) chain is expressed in a few specialized basement membranes in the body such as the GBM, the alveolar basement membrane, basement membranes in the testis, the inner ear, the eye and the choroid plexus [6] . IgG antibodies against 3(IV)NC1 bind to these basement membranes and activate the classical pathway of the complement system, which start a neutrophil dependent inflammation. Overt clinical symptoms are most prominent in the glomeruli where the inflammation usually results in a severe rapidly progressive glomerulonephritis.
Despite modern treatment less than one third of the patients survive with a preserved kidney function after 6 months follow-up [7, 8] .
Numerous animal models have been described showing the pathogenic role of the anti-GBM antibodies. In a classic experiment, primates developed glomerulonephritis after injection of autoantibodies eluted from the kidneys of a nephrectomised patient suffering from anti-GBM disease [4] . Indirect proof of the pathogenic potential of the antibodies was given by the reappearance of disease in a renal transplant given to a patient with persistent high levels of circulating anti-GBM antibodies. Temporal relationships between relapse and reoccurrence of autoantibodies have also been reported [9] . The titre of circulating anti-GBM antibodies, as measured by ELISA, has been shown to have prognostic importance [7, 10] .
In 1984 it was shown that the anti-GBM antibodies reacted with peptides around 25 and 50 kD and these were later shown to be derived from the non-collagenous domain (NC1) of type IV collagen [5] . The peptides were identified as a new chain of type IV collagen, the 3-chain. It was also shown that the epitope were cryptic and hidden in the NC1 hexamer The origin of the anti-GBM antibodies is still not known but interestingly naturally occurring anti-GBM antibodies of IgG class have been found in all healthy individuals.
These antibodies have low affinity and low titres but are specifically directed against the same epitopes found in patients with anti-GBM disease [20] .
Genetics
Genetic studies have revealed a strong link to exist between anti-GBM disease and 
Epidemiology
Published patient series have come from New Zealand, Australia, UK, the US, China, and Scandinavia and estimated frequencies varies from 0,5 -1 cases per million inhabitants per year [7, 23, 24] . No major differences between Asian and Caucasian populations are found, as seen in many other diseases. There are two peaks of agedependent incidence, in the third and in the seventh decades. The disease is uncommon before puberty and the male to female ratio is about equal in modern series from
Caucasians, but in older series and in reports from China males dominate [7, 22, 25] .
Environmental agents
Several attempts have been made to find an association with viral infections but only anecdotal case reports have been published. Some reports describe the development of anti-GBM disease after lithotripsy treatment for renal stones, but this association was not confirmed in a larger study [26] . Exposure to chemical agents, such as organic solvents and cigarette smoke has also been proposed to be implicated. Smoking seems at least to predispose for lung manifestations of the disease has [27] . However there is no evidence that any of these factors can induce disease alone, although it is likely that all of them can turn an on-going subacute disease into an acute one. The limited epitope recognition is compatible with a potential role for molecular mimicry or selfimmunization with fragments of the antigen.
Clinical aspects 3.1 Clinical manifestations
The typical presentation is that of a reno-pulmonary syndrome i.e. the combination of renal and pulmonary insufficiency. However, many other types of presentations have been described (Table 1) . Most patients report some form of general prodromal symptoms such as fatigue and malaise but usually only confined to the preceding few weeks or months. In some series, more than 50%, of the patients present with only renal involvement. Virtually all have microscopic haematuria, many also have macroscopic haematuria and rapidly progressive renal insufficiency is common. Sometimes the progression is explosive leading to anuria within days, while a minority of cases experience a protracted course where the renal function is preserved for several months.
Proteinuria is usually modest but occasionally patients present with a nephrotic syndrome. shown to correlate to levels of circulating anti-GBM; such a relationship has never been found in pulmonary disease [7, 10] .
Pathological features
Light microscopy typically reveals general widespread crescent formation. 
Diagnostic criteria
The diagnosis of anti-GBM disease relies on the detection of anti-GBM antibodies in conjunction with glomerulonephritis and/or alveolitis. As described above there is a huge variation in severity of both renal and pulmonary engagement in anti-GBM disease. The diagnosis can be made also in patients with mild disease in both organs, even though this is uncommon in clinical practice. The symptoms are problematic to interpret only when features of other diseases simultaneously are present.
In most cases anti-GBM antibodies can be detected both in the circulation by serological methods (i.e. ELISA) and in the kidney by immunostaining of renal biopsies. However, sometimes these assays yield divergent results making the diagnosis more difficult. Several cases have been described where no circulating antibodies could be detected. There are several possible explanations for such findings. Immunostaining can give false positive results and it is well known that in for instance diabetes a nonspecific binding of IgG along the GBM can occur, which can be misinterpreted as anti-GBM disease. The half-life of circulating antibodies is much shorter (21 days) than the half-life of tissue bound antibodies (several months). Subsequently if the sample for diagnosis is taken after the autoantibody production has ceased the assay for circulating antibodies can be true negative. There are also reports of false negative testing, reasons for this can be autoantibodies reacting with other antigens or other epitopes than the usual anti-3(IV)NC1. We have recently reported on anti-GBM with predominance of IgG4 that reacted better with antigen coated during non-denaturing conditions [36] .
There are also reports of IgA anti-GBM reacting with other antigens. testing. This can be due to autoantibodies reacting with other antigens than 3(IV)NC1, and about 1% of sera sent for autoantibody testing contain unspecific reactivity.
Treatment and prognosis
The standard therapy today consists of the combination of high doses of glucocorticoids, cyclophosphamide and plasma-exchange. The rational with steroids is to halt neutrophil driven inflammation; with cyclophosphamide to stop autoantibody production and with plasma exchange to remove circulating autoantibodies. Such therapy is usually very successful if started early. If begun before s-creatinine has risen above 600 micromole/L (5 mg/dl) there is a good chance of renal survival [7, 37] . Even if the chance for renal recovery is small when treatment is started later, there are dialysis dependent cases that do recover. Considering that there is a risk for late onset of alveolar haemorrhage it may be unwise not to treat all patients. Patients should not be transplanted as long as circulating autoantibodies can be detected. When anti-GBM production has ceased, it is very rare with relapses; we found one case in 81 while Levy et al found 2 among 71 [7, 37] .
Concluding remarks
The clinical expression can vary but anti-GBM disease in man has a poor prognosis. far. Early recognition of cases is therefore mandatory and can be obtained by the use of sensitive assays. Anti-GBM disease has been thoroughly studied during the last 50 years and can be considered a model of autoimmune diseases in general. The disease can be transferred with the antibodies. The antigen is well known as the C-terminal end of the alpha-3 chain of type IV collagen and the cryptic epitope is well defined. Models of anti-GBM nephritis resembling of Goodpasture's disease is today one of the most widespread models used to study inflammatory processes. 
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